Skip to main content

All products are sold strictly for laboratory research use only. Not for human or veterinary consumption, diagnosis, or treatment. Not approved by the FDA.

Research Use Only
RIBOCORE
Browse ProductsMost PopularPurity ReportsResearchResearch Use OnlySupport
0
RIBOCORE

Research-use-only peptides, compounds, and analytical documentation for qualified laboratories and institutions.

Products

  • Catalog
  • Most Popular
  • New Releases
  • Bundles

Trust

  • Purity Reports
  • Quality & Testing
  • Research Blog
  • Research Use Only
  • Shipping Policy
  • Discreet Delivery
  • Guarantee
  • Support Center

Stay Updated

Join our researcher list for batch alerts and purity report updates.

© 2026 RIBOCORE ANALYTICAL. ALL PRODUCTS SOLD STRICTLY FOR LABORATORY RESEARCH USE ONLY.
PrivacyTerms of ServiceShippingResearch Use OnlyPurity Reports

Search results for "BPC-157"

Found 7 products

Categories

  • GLP-1 & Weight Management(22)
  • Recovery & Healing(7)
  • Growth Hormone Peptides(13)
  • Anti-Aging & Wellness(20)
  • Supplies & Accessories(24)
  • Bundles(4)

Brand

7 results

Clear filters
Selank 10mg
99.4% Purity
In Stock

Selank 10mg

  • Synthetic Tuftsin Analogue: Heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed Russian Academy of Sciences, tuftsin core + Pro-Gly-Pro extension for metabolic stability, 20+ years research
  • Multi-Modal Mechanism: Positive allosteric modulator of GABA-A receptors, upregulates BDNF (hippocampus/cortex), inhibits enkephalinase (IC50 15 μM), modulates monoamines, no tolerance/dependence
  • Clinical Status: Russian FDA approved 2009 for GAD/neurasthenia (intranasal 0.15%), RCT showed efficacy equal to medazepam with additional nootropic effects, no sedation/amnesia unlike benzodiazepines

$40.00

Semax 30mg
99.4% Purity
In Stock

Semax 30mg

  • ACTH(4-10) Analogue: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, developed 1982 Russian Academy, ACTH(4-7) + Pro-Gly-Pro extension for metabolic stability, 800+ publications, no hormonal activity
  • Multi-Modal Neuroprotection: BDNF upregulation (1.4× protein, 3× mRNA hippocampus), monoamine modulation (180% 5-HIAA), copper chelation (K_D 1.3×10⁻¹⁵ M), anti-amyloid activity, transcriptomic ischemia protection
  • Clinical Status: Russian FDA approved, List of Vital & Essential Drugs 2011, Phase I-II trials 1990-1996, extensive clinical use for stroke/cognitive disorders/optic neuropathy, low toxicity profile

$30.00

GLOW BLEND (50mg)
99.4% Purity
In Stock

GLOW BLEND (50mg)

  • Triple-Peptide Blend: BPC-157 + TB-500 + GHK-Cu for comprehensive tissue regeneration
  • Multi-Phase Coverage: Inflammation, angiogenesis, cell migration, and matrix remodeling
  • Research Formulation: 50mg total, ≥98% purity per component, lyophilized powder

$97.00

KLOW (80mg)
99.4% Purity
In Stock

KLOW (80mg)

  • Quad-Peptide Blend: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total)
  • Enhanced Anti-Inflammatory: KPV addition for NF-κB pathway inhibition and cytokine control
  • Comprehensive Regeneration: Cytoprotection, angiogenesis, collagen synthesis, and inflammation modulation

$110.00

KLOW
99.4% Purity
In Stock

KLOW

  • Advanced Quad-Peptide Research Formulation: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total), extends GLOW Blend with KPV for enhanced inflammation modulation
  • Comprehensive Repair Cascade: BPC-157 (cytoprotection, VEGFR2 activation), TB-500 (cell migration, angiogenesis), GHK-Cu (collagen synthesis, 4,000+ gene modulation), KPV (NF-κB inhibition, anti-inflammatory signaling)
  • KPV Anti-Inflammatory Mechanism: C-terminal tripeptide of α-MSH, NF-κB pathway inhibition, TNF-α/IL-1β/IL-6 suppression, NO melanotropic effects (lacks melanocortin core sequence required for MC1R activation)

$110.00

PT-141 10mg
99.4% Purity
In Stock

PT-141 10mg

  • FDA-Approved Melanocortin Agonist: Cyclic heptapeptide MC3R/MC4R agonist, approved June 2019 (Vyleesi) for premenopausal HSDD, 100+ publications, first melanocortin therapeutic for sexual function
  • CNS Mechanism: Crosses blood-brain barrier, activates hypothalamic MC4R in mPOA triggering dopamine release, melanocortin-dopamine integration, mesolimbic reward pathway modulation
  • Clinical Development: 43 completed trials with 3,500+ subjects, Phase 3 RECONNECT (n=1,267) showed +0.35 desire improvement, 58% vs 36% responder rates, well-characterized safety profile

$33.25

Thymosin Alpha-1
99.4% Purity
In Stock

Thymosin Alpha-1

  • 28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
  • Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
  • Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction

$49.00